PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email info@lamerie.com
Principia Presents Phase 1 Data of PRN1371 in Patients with …
2019年5月21日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pinetree Therapeutics Announces Exclusive Option and Global …
2024年7月24日 · Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live ...
2021年1月21日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Phanes Therapeutics, Inc. Announces Clinical Supply Agreement …
2024年5月9日 · PT217 is Phanes’ first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ ®) is Roche’s anti-PD-L1 monoclonal antibody; The clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the treatment of small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine ...
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN …
2021年3月2日 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Ranok Therapeutics Expands Clinical Testing of CHAMP® BRD4 …
2024年3月11日 · — Study follows ongoing Phase 1 trial in U.S. and will enroll patients in China to evaluate the first protein degrader developed using Ranok’s innovative CHAMP ® technology. BOSTON, MA, USA & HANGZHOU, China I March 11, 2024 I Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers ...
Small Molecules - Pipelinereview
2024年9月5日 · Trial Initiation Marks Septerna’s Transition to a Clinical-Stage Company Developing a Portfolio of Oral Small Molecule GPCR-Targeted Medicines Phase 1 Clinical Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-786 in Healthy Volunteers SOUTH SAN FRANCISCO, CA, USA I September 27, 2024 I Septerna, a clinical-stage biotechnology company ...
BiOneCure Therapeutics Announces FDA Clearance of …
2022年4月7日 · GERMANTOWN, MD, USA I April 6, 2022 I BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors.. The clinical study cleared by the FDA, known as StarBridge-1, is a Phase I/II, multicenter, open-label study to evaluate the ...
Ozempic® (semaglutide) approved in the US - Pipelinereview
2017年12月6日 · BAGSVAERD, Denmark I December 5, 2017 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic ® (semaglutide injection). Ozempic ® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.. Ozempic ®, the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide ...